39 results match your criteria: "Azienda USL-IRCCS Institute of Neurological Sciences[Affiliation]"

Article Synopsis
  • The study focuses on maintaining health-related quality of life (HRQoL) for glioma patients during their progression-free survival (PFS) period.
  • Analysis of HRQoL data from past trials shows that 47% of patients experienced deterioration in HRQoL despite not progressing in the disease, with only poor performance status being a significant factor linked to this decline.
  • The findings highlight the need for regular monitoring of patients' well-being throughout their treatment to identify and address HRQoL issues early on.
View Article and Find Full Text PDF

Medulloblastoma is a rare brain malignancy. Patients after puberty are rare and bear an intermediate prognosis. Standard treatment consists of maximal resection plus radio-chemotherapy.

View Article and Find Full Text PDF

How we treat medulloblastoma in adults.

ESMO Open

August 2021

Wilhelm Sander NeuroOncology Unit & Department of Neurology, University Hospital Regensburg, Regensburg, Germany. Electronic address:

Medulloblastoma is a rare tumour in postpubertal patients and adults that is potentially curable. Several subgroups have been defined that are associated with clinical features, have different prognoses, and in some cases offer personalized treatment options. In adults, the sonic hedgehog (SHH) subtype is the most common subtype, followed by the wingless (WNT) and group 4 subtypes.

View Article and Find Full Text PDF
Article Synopsis
  • Two methods for combining survival and health-related quality of life (HRQoL) data in glioma trials—Quality-adjusted effect sizes (QASES) and joint modeling (JM)—were evaluated for calculating "net clinical benefit."
  • In the EORTC 26951 trial, additional treatments improved overall survival but negatively impacted HRQoL, leading to a notable decrease in perceived survival benefit when adjusting for symptoms like appetite loss and nausea.
  • The findings indicate that while both methods provided different outcomes, accounting for HRQoL diminished the apparent benefits of survival from treatments in glioma trials.
View Article and Find Full Text PDF

Background: Different analytical methods may lead to different conclusions about the impact of treatment on health-related quality of life (HRQoL). This study aimed to examine 3 different methods to evaluate change in HRQoL and to study whether these methods result in different conclusions.

Methods: HRQoL data from 15 randomized clinical trials were combined (CODAGLIO project).

View Article and Find Full Text PDF

Background: Gliomas evade current therapies through primary and acquired resistance and the effect of temozolomide is mainly restricted to methylguanin-O6-methyltransferase promoter (MGMT) promoter hypermethylated tumors. Further resistance markers are largely unknown and would help for better stratification.

Methods: Clinical data and methylation profiles from the NOA-08 (104, elderly glioblastoma) and the EORTC 26101 (297, glioblastoma) studies and 398 patients with glioblastoma from the Heidelberg Neuro-Oncology center have been analyzed focused on the predictive effect of DNA damage response (DDR) gene methylation.

View Article and Find Full Text PDF

Background: The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria have been largely adopted in clinical practice. In a recent retrospective study, we assessed that the addition of the first site of metastatic disease to brain, bone, and liver improves prognostic stratification of patients with metastatic renal cell carcinoma (mRCC). Here, we performed an external validation in patients with mRCC.

View Article and Find Full Text PDF

Rare Primary Central Nervous System Tumors in Adults: An Overview.

Front Oncol

June 2020

Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.

Overall, tumors of primary central nervous system (CNS) are quite common in adults with an incidence rate close to 30 new cases/100,000 inhabitants per year. Significant clinical and biological advances have been accomplished in the most common adult primary CNS tumors (i.e.

View Article and Find Full Text PDF

Uterine leiomyosarcoma (uLMS) is a rare and aggressive malignancy with poor clinical outcomes. Even when localized, uLMS is associated with high rates of local and distant recurrences that are usually fatal. Common sites of recurrence are lung, liver, pelvic lymph nodes, and vertebral and long bones, though atypical patterns of recurrence have been described.

View Article and Find Full Text PDF

To assess the measures applied to reduce the spread of coronavirus disease (COVID-19) and the timing of their application in medical oncology departments. We surveyed all medical oncology departments from the Italian Emilia Romagna region via a multidomain questionnaire. The questions covered items on patients, healthcare workers, risk reduction measure and clinical trials.

View Article and Find Full Text PDF

Immune-checkpoint inhibitors (ICI) represent a concrete hope for patients with advanced solid tumors. Indeed, patients responding to these agents may experience a long-lasting response. Recently, results of interventional clinical trials investigated the role of ICIs in patients with glioblastoma.

View Article and Find Full Text PDF

European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) criteria are used to choose treatment in low-grade gliomas. However, no data exist on their concordance. Low-grade glioma patients treated at our institution from 1998 to 2015 and assessable for both RTOG and EORTC criteria were included to analyze their concordance.

View Article and Find Full Text PDF

Objective: Prognostic value of health-related quality of life (HRQoL) data may be important to inform patients in clinical practice and to guide clinical decision-making. Our study investigated the added prognostic value of HRQoL for overall survival (OS) and progression-free survival (PFS) in a large heterogeneous sample of glioma patients, besides known prognostic factors.

Methods: We included individual baseline data from previously published randomised controlled trials (RCTs) in glioma patients in which HRQoL was assessed through the European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-BN20 questionnaires.

View Article and Find Full Text PDF

Background: Precision medicine trials targeting the epidermal growth factor receptor (EGFR) in glioblastoma patients require selection for EGFR-amplified tumors. However, there is currently no gold standard in determining the amplification status of EGFR or variant III (EGFRvIII) expression. Here, we aimed to determine which technique and which cutoffs are suitable to determine EGFR amplification status.

View Article and Find Full Text PDF
Article Synopsis
  • Clinical factors like MGMT methylation status, age, KPS, and surgical resection are key in predicting glioblastoma (GBM) prognosis, with a noted advantage for female patients in survival rates.
  • In a study of 169 GBM patients, those with MGMT methylation showed longer survival, especially females compared to males; survival differences were not significant among unmethylated individuals.
  • Multivariate analysis confirmed that both gender and MGMT status, along with age and KPS, are important predictive factors for patient survival in GBM cases.
View Article and Find Full Text PDF

The members of the PERNO Study Group were not individually captured in the metadata of the original publication. They are included in the metadata of this publication.

View Article and Find Full Text PDF

Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts.

CNS Drugs

August 2017

Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL-IRCCS Institute of Neurological Sciences, Via Altura 3, 40139, Bologna, Italy.

Glioblastoma is the most frequent malignant brain tumor and is characterized by poor prognosis, increased invasiveness, and high recurrence rates. Standard treatment for glioblastoma includes maximal safe surgical resection, radiation, and chemotherapy with temozolomide. Despite treatment advances, only 15-20% of glioblastoma patients survive to 5 years, and no therapies have demonstrated a durable survival benefit in recurrent disease.

View Article and Find Full Text PDF

Galunisertib, a Transforming growth factor-βRI (TGF-βRI) kinase inhibitor, blocks TGF-β-mediated tumor growth in glioblastoma. In a three-arm study of galunisertib (300 mg/day) monotherapy (intermittent dosing; each cycle =14 days on/14 days off), lomustine monotherapy, and galunisertib plus lomustine therapy, baseline tumor tissue was evaluated to identify markers associated with tumor stage (e.g.

View Article and Find Full Text PDF

Background: methylation status represents a powerful prognostic factor in newly diagnosed glioblastoma (GBM). Recently, its role in recurrent tumors has also been suggested; however, few data investigating the stability of this biomarker during the clinical course of the disease are available. In this study, we evaluated the rate of change of methylation status between diagnosis and first recurrence in patients who received tumor resection for recurrent GBM.

View Article and Find Full Text PDF

MicroRNAs (miRNAs) are differentially expressed in the brain under pathologic conditions and may therefore represent both therapeutic targets and diagnostic or prognostic biomarkers for neurologic diseases, including epilepsy. In fact, miRNA expression profiles have been investigated in the hippocampi of patients with epilepsy in comparison with control, nonepileptic cases. Unfortunately, the interpretation of these data is difficult because surgically resected epileptic tissue is generally compared with control tissue obtained from autopsies.

View Article and Find Full Text PDF

Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences.

Curr Treat Options Oncol

September 2016

Department of Medical Oncology, Bellaria Hospital, Azienda USL-IRCCS Institute of Neurological Sciences, Via Altura 4, Bologna, Italy.

At the time of glioblastoma (GBM) recurrence, a sharp analysis of prognostic factors, disease characteristics, response to adjuvant treatment, and clinical conditions should be performed. A prognostic assessment could allow a careful selection between patients that could be proposed to intensified approaches or palliative setting. Participation in clinical trials aims to improve outcome, and should be encouraged due to dismal prognosis of GBM patients after recurrence.

View Article and Find Full Text PDF